Diabetes medications and cardiovascular outcome trials: Lessons learned

Cleve Clin J Med. 2017 Oct;84(10):759-767. doi: 10.3949/ccjm.84gr.17006.

Abstract

The US Food and Drug Administration's current standards require that new diabetes medications demonstrate cardiovascular safety in large, long-term trials. New drugs that have been assessed in such trials are changing the management of type 2 diabetes.

Publication types

  • Review

MeSH terms

  • Cardiovascular Diseases / chemically induced*
  • Clinical Trials as Topic
  • Diabetes Mellitus, Type 2 / drug therapy
  • Humans
  • Hypoglycemic Agents / adverse effects*
  • Hypoglycemic Agents / therapeutic use

Substances

  • Hypoglycemic Agents